All In Biotech

Drug Trial Radar · NCT07392736

A Phase I/IIa Study of AL8326 Combined With Toripalimab in the Treatment of Advanced Solid Tumors.

A Phase I/IIa Clinical Trial of AL8326 Tablets Combined With Toripalimab in the Treatment of Advanced Recurrent or Metastatic Solid Tumors

Last checked: Nov 19, 2026Latest source record: Feb 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

228

Planned (sponsor's estimate)

Start

Oct 26, 2021

Primary completion

Nov 7, 2029

Study completion Nov 7, 2029

Sponsor

Lead sponsor
Advenchen Laboratories, LLCIndustry
Sponsor type
Industry
First posted
Feb 6, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Screening
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This trial is an open, non-randomized, phase I/IIa clinical trial, which will evaluate the preliminary effectiveness and safety of AL8326 tablets in patients with advanced solid tumors

Conditions

  • Solid Tumor

Interventions

  • AL8326 tabletsDrug

    Tablet: 10mg/tablet; administered orally once daily

  • ToripalimabDrug

    240mg Injection solution:21-Day cycles

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The first part (Phase I): Phase II recommended dose (RP2D)Time frame: At the end of Cycle 1 (each cycle is 28 days)
  2. The second part (Phase IIa):Objective remission rate (ORR)Time frame: Every 2/3/4 cycles,up to 24 month(each cycle is 21 days)

Locations

15 sites in 1 country. Site status is shown where the registry gives one.

  • National GCP Center for Anticancer Drugs,The Independent Ethics Committee

    Beijing, Beijing Municipality, China · Recruiting

  • The Cancer Hospital of the Chinese Academy of Medical Sciences

    Beijing, Beijing Municipality, China · Recruiting

  • Hunan Cancer Hospital

    Hunan, Changsha, China · Recruiting

  • Fujian Cancer Hospital

    Fuzhou, Fujian, China · Recruiting

  • Cancer Hospital of Shantou University Medical College

    Shantou, Guangdong, China · Recruiting

  • Yuebei People's Hospital

    Shaoguan, Guangdong, China · Recruiting

  • The First Affiliated Hospital of Guilin Medical Universty

    Guilin, Guangxi, China · Recruiting

  • Liuzhou Workers' Hospital

    Liuzhou, Guangxi, China · Recruiting

  • The People's Hospital of Guangxi Zhuang Autonomous Region

    Nanning, Guangxi, China · Recruiting

  • Guangxi Medical University Cancer Hospital

    Nanning, Guangxi, China · Recruiting

  • Henan Cancer Hospital

    Zhengzhou, Henan, China · Recruiting

  • The First Affiliated Hospital of Zhengzhou University

    Zhengzhou, Henan, China · Recruiting

  • The First Affiliated Hospital of Xi'an Jiaotong University

    Xi’an, Shanxi, China · Recruiting

  • Zhejiang Cancer Hospital

    Hangzhou, Zhejiang, China · Recruiting

  • SIR RUN RUN SHAW Hospital Zhejiang University School Of Medicine

    Hangzhou, Zhejiang, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.